Efficacy and Safety of Treat-and-Extend Regimen Versus Pro Re Nata of Conbercept in Age-related Macular Degeneration
A Multicenter Study Comparing Efficacy and Safety of Treat-and-Extend Regimen Versus Pro Re Nata Regimen of Conbercept in Neovascular Age-related Macular Degeneration
Sponsor: Eye & ENT Hospital of Fudan University
This PHASE4 trial investigates Age-related Macular Degeneration and is currently ongoing. Eye & ENT Hospital of Fudan University leads this study, which shows 10 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Jun 2022 — Jul 2024 [monthly]
Unknown Status PHASE4
Status: Active Not Recruiting → Unknown Status
-
Oct 2021 — Jun 2022 [monthly]
Active Not Recruiting PHASE4
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE4
▶ Show 5 earlier versions
-
Jun 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE4
Status: Unknown Status → Active Not Recruiting
-
Jan 2019 — Jun 2020 [monthly]
Unknown Status PHASE4
Status: Not Yet Recruiting → Unknown Status
-
Jun 2018 — Jan 2019 [monthly]
Not Yet Recruiting PHASE4
-
Jun 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE4
-
Jan 2017 — Jun 2017 [monthly]
Not Yet Recruiting PHASE4
First recorded
Sep 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eye & ENT Hospital of Fudan University
- Shanghai Tongji Hospital, Tongji University School of Medicine
- Shanghai Zhongshan Hospital
- The General Hospital of Central Theater Command
- Xiaodong Sun
For direct contact, visit the study record on ClinicalTrials.gov .